Clinical Trials Using Pacritinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Pacritinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P / C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000 / μL). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or to P / C therapy (approximately 116 patients) Condition or disease: Primary Myelofibrosis / Post-Polycythemia Vera Myelofibrosis / Post-essential Thrombocythemia Myelofibrosis Intervention / treatment: Drug-Pacritinib
Location: 22 locations
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Pacritinib in Treating Patients with Relapsed or Refractory Lymphoproliferative Disorders
This phase Ib trial studies the side effects of pacritinib in treating patients with lymphoproliferative disorders that have come back or do not respond to treatment. Pacritinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Pacritinib, Sirolimus, and Tacrolimus in Preventing Graft Versus Host Disease in Patients with Blood Cancer Undergoing Donor Stem Cell Transplant
This phase I / II trial studies the best dose and side effects of pacritinib when given together with sirolimus and tacrolimus and to see how well they work in preventing graft versus host disease in patients with blood cancer undergoing donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells called graft versus host disease. Giving pacritinib, sirolimus, and tacrolimus after the transplant may stop this from happening.
Location: Moffitt Cancer Center, Tampa, Florida